Luminal 5-HT4 receptors-A successful target for prokinetic actions. 2019

Rachel M Gwynne, and Joel C Bornstein
Department of Physiology, University of Melbourne, Parkville, Vic., Australia.

The prokinetic effects of 5-HT4 receptor (5-HT4 R) agonists have been utilized clinically for almost three decades to relieve symptoms of constipation. Surprisingly, the mechanism(s) of action of these compounds is still being debated. Recent studies highlight luminal 5-HT4 Rs as an alternative and effective target for these prokinetic agents. These include the study by Shokrollahi et al (2019, Neurogastroenterol Motil, e13598) published in the current issue of Neurogastroenterology and Motility, who found that activation of mucosal 5-HT4 Rs by intraluminal prucalopride, significantly enhanced propulsive motor patterns in rabbit colon. The authors highlight the idea that development of agonists targeting luminal 5-HT4 Rs in the colonic mucosa might be more effective and safer in achieving prokinetic effects on intestinal motility. The purpose of this mini-review is to discuss the evidence for luminal 5-HT4 Rs as an emerging target for prokinetic agents in facilitating propulsive motor patterns in the colon.

UI MeSH Term Description Entries
D007413 Intestinal Mucosa Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI. Intestinal Epithelium,Intestinal Glands,Epithelium, Intestinal,Gland, Intestinal,Glands, Intestinal,Intestinal Gland,Mucosa, Intestinal
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011812 Quinuclidines A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group. Quinuclidine
D003106 Colon The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON. Appendix Epiploica,Taenia Coli,Omental Appendices,Omental Appendix,Appendices, Omental,Appendix, Omental
D003248 Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections. Colonic Inertia,Dyschezia
D005769 Gastrointestinal Motility The motor activity of the GASTROINTESTINAL TRACT. Intestinal Motility,Gastrointestinal Motilities,Intestinal Motilities,Motilities, Gastrointestinal,Motilities, Intestinal,Motility, Gastrointestinal,Motility, Intestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001549 Benzamides BENZOIC ACID amides.
D001572 Benzofurans Compounds that contain a BENZENE ring fused to a furan ring. Coumarones,Diphenylbenzofuran
D044422 Receptors, Serotonin, 5-HT4 A subtype of G-protein-coupled SEROTONIN receptors that preferentially couple to GS STIMULATORY G-PROTEINS resulting in increased intracellular CYCLIC AMP. Several isoforms of the receptor exist due to ALTERNATIVE SPLICING of its mRNA. Receptors, Serotonin, 5-HT4L,Receptors, Serotonin, 5-HT4S,Serotonin 4 Receptor,5-HT4 Receptor,5-HT4L Receptor,5-HT4S Receptor,5-Hydroxytryptamine-4 Receptor,Receptor, Serotonin 4,Serotonin 4 Receptors,5 HT4 Receptor,5 HT4L Receptor,5 HT4S Receptor,5 Hydroxytryptamine 4 Receptor,Receptor, 5-HT4,Receptor, 5-HT4L,Receptor, 5-HT4S,Receptor, 5-Hydroxytryptamine-4,Receptors, Serotonin 4

Related Publications

Rachel M Gwynne, and Joel C Bornstein
April 2021, Neurogastroenterology and motility,
Rachel M Gwynne, and Joel C Bornstein
April 2021, Neurogastroenterology and motility,
Rachel M Gwynne, and Joel C Bornstein
July 1991, Pharmacological research,
Rachel M Gwynne, and Joel C Bornstein
February 2004, Current drug targets. CNS and neurological disorders,
Rachel M Gwynne, and Joel C Bornstein
November 2004, Bioorganic & medicinal chemistry letters,
Rachel M Gwynne, and Joel C Bornstein
January 2022, Advances in experimental medicine and biology,
Rachel M Gwynne, and Joel C Bornstein
October 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Rachel M Gwynne, and Joel C Bornstein
November 1995, Trends in pharmacological sciences,
Rachel M Gwynne, and Joel C Bornstein
May 2004, Current Alzheimer research,
Rachel M Gwynne, and Joel C Bornstein
November 1991, European journal of pharmacology,
Copied contents to your clipboard!